UBS Group Issues Pessimistic Forecast for Cabot (NYSE:CBT) Stock Price

Cabot (NYSE:CBT) had its price objective decreased by equities researchers at UBS Group from $93.00 to $83.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “neutral” rating on the specialty chemicals company’s stock. UBS Group’s price objective would suggest a potential upside of 9.79% from the company’s current price.

A number of other equities analysts have also weighed in on the stock. StockNews.com upgraded shares of Cabot from a “hold” rating to a “buy” rating in a research report on Tuesday, April 1st. Mizuho lowered their target price on shares of Cabot from $122.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Cabot from $105.00 to $85.00 and set an “underweight” rating for the company in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Cabot has an average rating of “Hold” and an average price target of $93.25.

Cabot Stock Performance

NYSE:CBT traded down $2.67 during trading hours on Monday, reaching $75.60. 571,729 shares of the company’s stock were exchanged, compared to its average volume of 382,109. Cabot has a 1-year low of $74.87 and a 1-year high of $117.46. The company has a quick ratio of 1.29, a current ratio of 2.00 and a debt-to-equity ratio of 0.72. The firm has a market capitalization of $4.10 billion, a price-to-earnings ratio of 10.17, a P/E/G ratio of 0.74 and a beta of 1.04. The company has a 50-day moving average of $84.85 and a 200 day moving average of $97.31.

Cabot (NYSE:CBT) last announced its earnings results on Monday, February 3rd. The specialty chemicals company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.74 by $0.02. Cabot had a net margin of 10.60% and a return on equity of 26.79%. Research analysts anticipate that Cabot will post 7.57 EPS for the current year.

Hedge Funds Weigh In On Cabot

Hedge funds have recently bought and sold shares of the company. R Squared Ltd acquired a new position in shares of Cabot during the 4th quarter worth $26,000. EverSource Wealth Advisors LLC raised its position in shares of Cabot by 37.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 808 shares of the specialty chemicals company’s stock valued at $74,000 after buying an additional 219 shares during the last quarter. GAMMA Investing LLC boosted its position in Cabot by 10.7% during the fourth quarter. GAMMA Investing LLC now owns 1,348 shares of the specialty chemicals company’s stock worth $123,000 after acquiring an additional 130 shares during the last quarter. Manchester Capital Management LLC grew its stake in Cabot by 1,685.1% in the 4th quarter. Manchester Capital Management LLC now owns 1,678 shares of the specialty chemicals company’s stock worth $153,000 after acquiring an additional 1,584 shares during the period. Finally, KBC Group NV lifted its stake in shares of Cabot by 43.1% during the 4th quarter. KBC Group NV now owns 2,046 shares of the specialty chemicals company’s stock worth $187,000 after purchasing an additional 616 shares during the period. 93.18% of the stock is owned by hedge funds and other institutional investors.

Cabot Company Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.